These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 11454687

  • 1. Inhibition of DNA replication by tirapazamine.
    Peters KB, Wang H, Brown JM, Iliakis G.
    Cancer Res; 2001 Jul 15; 61(14):5425-31. PubMed ID: 11454687
    [Abstract] [Full Text] [Related]

  • 2. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
    Evans JW, Yudoh K, Delahoussaye YM, Brown JM.
    Cancer Res; 1998 May 15; 58(10):2098-101. PubMed ID: 9605751
    [Abstract] [Full Text] [Related]

  • 3. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia.
    Siim BG, Menke DR, Dorie MJ, Brown JM.
    Cancer Res; 1997 Jul 15; 57(14):2922-8. PubMed ID: 9230202
    [Abstract] [Full Text] [Related]

  • 4. DNA-targeted 1,2,4-benzotriazine 1,4-dioxides: potent analogues of the hypoxia-selective cytotoxin tirapazamine.
    Hay MP, Pruijn FB, Gamage SA, Liyanage HD, Kovacs MS, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2004 Jan 15; 47(2):475-88. PubMed ID: 14711317
    [Abstract] [Full Text] [Related]

  • 5. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB, Brown JM.
    Cancer Res; 2002 Sep 15; 62(18):5248-53. PubMed ID: 12234992
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2003 Jan 02; 46(1):169-82. PubMed ID: 12502371
    [Abstract] [Full Text] [Related]

  • 7. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.
    Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang J, MacDermed D, Chiu RK, Brown JM.
    Cancer Res; 2001 Jan 01; 61(1):145-52. PubMed ID: 11196153
    [Abstract] [Full Text] [Related]

  • 8. Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
    Hellauer K, Lesage G, Sdicu AM, Turcotte B.
    Mol Pharmacol; 2005 Nov 01; 68(5):1365-75. PubMed ID: 16061773
    [Abstract] [Full Text] [Related]

  • 9. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
    Yang B, Keshelava N, Anderson CP, Reynolds CP.
    Cancer Res; 2003 Apr 01; 63(7):1520-6. PubMed ID: 12670899
    [Abstract] [Full Text] [Related]

  • 10. Tirapazamine cytotoxicity for neuroblastoma is p53 dependent.
    Yang B, Reynolds CP.
    Clin Cancer Res; 2005 Apr 01; 11(7):2774-80. PubMed ID: 15814660
    [Abstract] [Full Text] [Related]

  • 11. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.
    Delahoussaye YM, Hay MP, Pruijn FB, Denny WA, Brown JM.
    Biochem Pharmacol; 2003 Jun 01; 65(11):1807-15. PubMed ID: 12781332
    [Abstract] [Full Text] [Related]

  • 12. Tirapazamine: laboratory data relevant to clinical activity.
    Brown JM, Wang LH.
    Anticancer Drug Des; 1998 Sep 01; 13(6):529-39. PubMed ID: 9755717
    [Abstract] [Full Text] [Related]

  • 13. Carbonic anhydrase 9 (CA9) expression in tumor cells enhances sensitivity to tirapazamine.
    Shin HJ, Kim JY, Yoo CW, Roberts SA, Lee S, Choi SJ, Lee HY, Lee DH, Kim TH, Cho KH.
    J Cancer Res Clin Oncol; 2008 Mar 01; 134(3):397-404. PubMed ID: 17724612
    [Abstract] [Full Text] [Related]

  • 14. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway.
    Nagasawa H, Mikamo N, Nakajima Y, Matsumoto H, Uto Y, Hori H.
    Anticancer Res; 2003 Mar 01; 23(6a):4427-34. PubMed ID: 14666730
    [Abstract] [Full Text] [Related]

  • 15. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.
    Hicks KO, Pruijn FB, Sturman JR, Denny WA, Wilson WR.
    Cancer Res; 2003 Sep 15; 63(18):5970-7. PubMed ID: 14522924
    [Abstract] [Full Text] [Related]

  • 16. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 15; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

  • 17. Metabolism of tirapazamine by multiple reductases in the nucleus.
    Delahoussaye YM, Evans JW, Brown JM.
    Biochem Pharmacol; 2001 Nov 01; 62(9):1201-9. PubMed ID: 11705453
    [Abstract] [Full Text] [Related]

  • 18. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul 01; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

  • 19. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 20. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG, Wang LH, Brown JM.
    Ann Oncol; 1999 Jul 15; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.